Rating upgraded from 66 to 73 Tuesday — a welcome improvement, but still shy of the 80 or better score you prefer to see.

Pfizer and GlaxoSmithKline have agreed to end a lawsuit over alleged patent infringement involving their competing respiratory syncytial virus (RSV) vaccines, according to a filing made in Delaware ...

Amid the current market turmoil, it is worth remembering that the pharmaceutical industry must continue its normal business of ensuring that it has products to sell in 10 years, with GSK (GSK) signing ...

NEW YORK CITY, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK plc (“GSK” or “the Company”) (NYSE: GSK) for violations of ...

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South Korean company’s tech to bypass the blood-brain barrier. ABL Bio has ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier. GSK is fronting £38.5 million (nearly $50 million), in a partnership with ...

NEW YORK CITY, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies ...

GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware federal court. The deal blocks the parties from renewing their claims or ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other most undervalued healthcare stocks to buy according to analysts. Healthcare prices and expenditures ...